Original ArticlesA Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer
Key Words
Cited by (0)
Disclosure: This work was supported by Genentech and the Dana-Farber/Harvard Cancer Center SPORE in Lung Cancer, National Cancer Institute P50 CA090578 (JES).
Joel Neal received research funding from Genentech. Panos Fidias is on the advisory board for Genentech. Alice Shaw has consulted for Pfizer, Ariad, Chugai, Novartis, Millenium, and Daiichi. Thomas Lynch is a consultant for Merck, Supergen, and Boehringer-Ingelheim, is on the Board of Directors for Infinity, and is a joint holder for a patent for EGFR mutation testing. Sreenath Sharma received a grant from the LUNGevity Foundation & Goldman Philanthropic Partnerships, consulted for Concert Pharmaceuticals, and is employed by Norvartis. Jeffrey Settleman is employed by Genentech. Lecia Sequist received a grant from Genentech and is on the advisory boards for Clovis Oncology, Celgene, GSK, Daiichi Sankyo, and Merrimack. The remaining authors declare no conflict of interest.